Mexico Point of Care Diagnostics Market (2024-2029)
The Mexico Point of Care Diagnostics Market was valued at $71.9 Million in 2024 and projected to reach to $100.9 Million by 2029, representing a compound annual growth rate of 7.0%. Mexico's Point of Care Diagnostics Market is positioned for steady growth through 2029, driven by healthcare modernization efforts and increased investment in diagnostic infrastructure.
Mexico Point of Care Diagnostics Market Trends and Insights
- Mexico's market growth is driven by increasing healthcare accessibility in rural and underserved regions, rising prevalence of chronic diseases, and growing adoption of rapid diagnostic technologies across clinical and non-clinical settings.
- The expansion reflects Mexico's commitment to strengthening primary healthcare infrastructure and improving diagnostic capabilities at the point of care. In Mexico, the Point of Care Diagnostics Market benefits from favorable demographic trends, including a large population base and rising healthcare expenditure.
- Mexico's healthcare system increasingly recognizes the value of rapid, cost-effective diagnostic solutions to reduce patient wait times and improve clinical outcomes.
- Between 2024 and 2029, Mexico is expected to see accelerated adoption of POC testing devices in hospitals, clinics, pharmacies, and home-care settings, supported by regulatory improvements and private sector investment..
Key Market Statistics
- CAGR (2024-2029) 7.0% CAGR
- Market Size, 2024 ~USD 71.9 Million
- Forecast, 2029 ~USD 100.9 Million
- Country Mexico
Mexico Point of Care Diagnostics Market Overview
Market Valuation :
Mexico's Point of Care Diagnostics Market is valued at USD 71.9 million in 2024, with projected growth to USD 100.9 million by 2029, demonstrating strong market expansion opportunities.
Rural Healthcare Expansion :
Increasing healthcare accessibility initiatives in Mexico's rural and underserved regions are driving significant adoption of point-of-care diagnostic solutions, bridging the gap in medical infrastructure.
Chronic Disease Burden :
Rising prevalence of chronic diseases including diabetes, hypertension, and cardiovascular conditions in Mexico is accelerating demand for rapid, accessible diagnostic technologies in both clinical and community settings.
Rapid Technology Adoption :
Growing adoption of rapid diagnostic technologies across Mexican healthcare facilities reflects increasing recognition of point-of-care testing's efficiency, cost-effectiveness, and ability to improve patient outcomes.
Mexico Point of Care Diagnostics Market Dynamics
- The 7% CAGR reflects Mexico's commitment to expanding healthcare access beyond urban centers, with particular emphasis on rapid testing solutions for infectious diseases and chronic condition management.
- Government initiatives promoting preventive healthcare and the rising middle class's demand for quality diagnostics will continue to fuel market expansion.
- Additionally, partnerships between local healthcare providers and international diagnostic manufacturers are expected to accelerate technology adoption and market penetration across Mexico's diverse healthcare landscape..
Related Ecosystem
In Vitro Diagnostics
- Polymerase Chain Reaction (PCR)
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Dna Microarrays
- Assay Kits
- Microarrays
- ROCHE HOLDINGS AG
- Thermo Fisher Scientific Inc.
- Danaher Corporation
- Abbott Laboratories
- Biomerieux s.a.
Medical Devices
- Polymerase Chain Reaction (PCR)
- Magnetic Resonance Imaging (MRI)
- Disposable Autoinjectors
- Pulse Oximeters
- Blood Pressure Monitors
- Medtronic plc
- Stryker Corporation
- Abbott Laboratories
- Becton, Dickinson and Company
- JOHNSON & JOHNSON
Key Takeaways
- Mexico's Point of Care Diagnostics Market is valued at USD 71.9 million in 2024 and will reach USD 100.9 million by 2029 at a 7.0% CAGR.
- Mexico's market growth is driven by expanding healthcare access, rising chronic disease prevalence, and increased adoption of rapid diagnostic technologies.
- Mexico's healthcare system is increasingly integrating POC testing in hospitals, clinics, pharmacies, and home-care settings to improve diagnostic efficiency.
- Mexico's regulatory environment and private sector investment are accelerating the adoption of Point of Care Diagnostics solutions across the country.
Point of Care Diagnostics Market Report Scope
| Report Metric | Details |
|---|---|
| Base Year | 2024 |
| Fastest Growing Segment | INFECTIOUS DISEASE TESTING PRODUCTS (Product) |
| Forecast Period | 2024–2029 |
| Growth Rate | CAGR of 8.5% from 2024 to 2029 |
| Largest Segment | BLOOD SAMPLES (Sample) |
| Market Size Base Year (Billions) | ~USD 15.05 (2024) |
| Revenue Forecast (Billions) | ~USD 22.63 (2029) |
| Segments Covered | Product, Type, Sample, End User, Mode Of Purchase, Technology |
Mexico Point of Care Diagnostics Market Report Segmentation
6 segment dimensions are covered across the global market.
By Product
- Cardiometabolic Monitoring Products
- Cholesterol Testing Products
- Coagulation Monitoring Products
- Drugs-Of-Abuse Testing Products
- Fecal Occult Testing Products
- Glucose Monitoring Products
- Hematology Testing Products
- Infectious Disease Testing Products
- Other Products
- Pregnancy & Fertility Testing Products
- Thyroid Stimulating Hormone Testing Products
- Tumor/Cancer Marker Testing Products
- Urinalysis Testing Products
By Type
- Act/Apit Testing Products
- Blood Gas/ Electrolyte Testing Products
- Cardiac Marker Testing Products
- Chlamydia Trachomatis Testing Products
- Clostridium Difficile Infection Testing Products
- Fertility Testing Products
- Glucose Monitoring Lancets & Lancing Devices
- Glucose Monitoring Meters
- Glucose Monitoring Strips
- Hba1C Testing Products
- Healthcare-Associated Infection Testing Products
- Hepatitis B Testing Products
- Hepatitis C Testing Products
- Hepatitis Testing Products
- Herpes Simplex Virus Testing Products
- Hiv Testing Products
- Human Papillomavirus Testing Products
- Inaat
- Influenza Testing Products
- Meters
- Neisseria Gonorrhea Testing Products
- Neisseria Gonorrhoea Testing Products
- Other Infectious Disease Testing Products
- Other Respiratory Infection Testing Products
- Pregnancy Testing Products
- Pt/Inr Testing Products
- Respiratory Infection Testing Products
- Rt-Pcr
- Sexually Transmitted Disease Testing Products
- Strips
- Syphilis Testing Products
- Tropical Disease Testing Products
- Tuberculosis
By Sample
- Blood Samples
- Nasal & Oropharyngeal Swabs
- Other Samples
- Urine Samples
By End User
- Ambulatory Care Facilities And Physician Offices
- Clinical Laboratories
- Home Care Settings And Self-Testing
- Hospitals, Critical Care Centers, And Urgent Care Centers
- Other End Users
By Mode Of Purchase
- Otc Testing Products
- Prescription-Based Testing Products
By Technology
- Biochemistry
- Immunoassays
- Molecular Diagnostics
Target Audience
- Diagnostic Device Manufacturers : Manufacturers seeking to expand operations in Mexico need market-specific data on demand drivers, regulatory pathways, and distribution opportunities to successfully launch and scale point-of-care diagnostic products.
- Healthcare Providers & Hospitals : Mexican healthcare institutions require insights into market trends, technology adoption rates, and competitive offerings to make informed procurement decisions and optimize diagnostic capabilities.
- Investment & Private Equity Firms : Investors evaluating opportunities in Mexico's healthcare sector need comprehensive market analysis, growth projections, and risk assessments to identify promising companies and investment targets.
- Government & Policy Makers : Mexican health authorities and policymakers benefit from market intelligence to develop evidence-based healthcare policies, allocate resources effectively, and support diagnostic infrastructure development.
- Distributors & Healthcare Retailers : Distribution partners and healthcare retailers need Mexico-specific market data to understand demand patterns, identify growth segments, and optimize inventory and sales strategies.
Key Companies in the Mexico Point of Care Diagnostics Market
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| CEPHEID INC. | United States | Private Company | Infectious Disease POC (TB, HAI, STD, virology),Oncology and Genetics POC / near-patient MDx,Other POC (including emergency use, emerging pathogens such as Ebola), |
| UNILABS | Switzerland | Private Company | Glucose POC (primarily hospital and clinic-based),Infectious Disease POC (TB, HAI, STD),Pregnancy and Fertility-Linked POC, |
| EIKEN CHEMICAL CO., LTD. | Japan | Public Company | Glucose (POC),Infectious Disease POC (TB, HAI, STD and others),Pregnancy and other immunological POC tests, |
| ABBOTT | United States | Public Company | Glucose (POC and home monitoring within scope),Infectious Disease POC (including TB, HAI, STD, respiratory, HIV, others),Pregnancy and fertility POC, |
| SIEMENS HEALTHINEERS AG | Germany | Public Company | Glucose (Rx and OTC POC),Infectious Disease POC (TB, HAI, STD and others),Pregnancy and Fertility POC, |
| DANAHER | United States | Public Company | Glucose POC,Infectious Disease POC (incl. TB, HAI, STD),Pregnancy and Fertility POC, |
| QUIDELORTHO CORPORATION | United States | Public Company | POC Infectious Disease (incl. TB, HAI, STD, respiratory),POC Pregnancy and Fertility,POC Glucose and Metabolic, |
| BD | United States | Public Company | Glucose POC,Infectious Disease POC (TB, HAI, STD),Pregnancy and Other POC, |
| THERMO FISHER SCIENTIFIC INC. | United States | Public Company | Glucose POC,Infectious Disease POC (TB, HAI, STD and others),Pregnancy and Fertility POC, |
| BIOMéRIEUX | France | Public Company | Infectious Disease POC (TB, HAI, STD, respiratory via BIOFIRE/SPOTFIRE, ARGENE near-patient use),Pregnancy and other immunoassay POC (VIDAS and related markers in near-patient settings),Glucose and basic biochemistry POC, |
| BIOSYNEX SA | France | Public Company | Glucose POC,Infectious Disease POC (TB, HAI, STD and others),Pregnancy and Fertility POC, |
| EKF DIAGNOSTICS HOLDINGS PLC | United Kingdom | Public Company | Glucose and Lactate Analyzers (Biosen, Lactate Scout, related),HbA1c and Hemoglobin POC Analyzers (Quo-Lab, Quo-Test, DiaSpect, Hemo Control, Hemo Vet),Pregnancy and Fertility (QuPID, True20, Creamatocrit Plus), |
| TRINITY BIOTECH | Ireland | Public Company | Glucose / Diabetes (incl. HbA1c-linked POC),Infectious Disease POC (TB, HAI, STD, viral),Pregnancy and Fertility POC, |
| BODITECH MED INC. | South Korea | Public Company | Glucose (POC),Infectious Disease (TB, HAI, STD, COVID-19 and others),Pregnancy and Fertility, |
CEPHEID INC.
CEPHEID INC. is a United States-based private company founded in 1996 with 1,700 employees specializing in molecular diagnostics.
UNILABS
UNILABS is a Swiss private company established in 1987 that operates clinical laboratory services with 1,897 employees.
EIKEN CHEMICAL CO., LTD.
EIKEN CHEMICAL CO., LTD. is a Japanese public company founded in 1939 with 696 employees engaged in chemical and diagnostic manufacturing.
ABBOTT
ABBOTT is a United States-based public company founded in 1888 with 115,000 employees operating in healthcare and diagnostics.
SIEMENS HEALTHINEERS AG
SIEMENS HEALTHINEERS AG is a German public company founded in 1896 with 72,369 employees providing medical technology and diagnostics solutions.
DANAHER
DANAHER is a United States-based public company founded in 1969 with 59,000 employees operating in diagnostics and life sciences.
QUIDELORTHO CORPORATION
QUIDELORTHO CORPORATION is a United States public company founded in 1979 with 6,500 employees specializing in diagnostic testing.
BD
BD is a United States-based public company founded in 1897 with 72,000 employees in medical technology and diagnostics.
THERMO FISHER SCIENTIFIC INC.
THERMO FISHER SCIENTIFIC INC. is a United States public company founded in 1956 with 125,000 employees providing life sciences and diagnostics solutions.
BIOMéRIEUX
BIOMéRIEUX is a French public company founded in 1963 with 14,894 employees specializing in in vitro diagnostics.
BIOSYNEX SA
BIOSYNEX SA is a French public company founded in 2005 with 397 employees in the diagnostic testing sector.
EKF DIAGNOSTICS HOLDINGS PLC
EKF DIAGNOSTICS HOLDINGS PLC is a United Kingdom public company founded in 1990 with 301 employees in clinical diagnostics.
TRINITY BIOTECH
TRINITY BIOTECH is an Irish public company founded in 1992 with 287 employees engaged in diagnostic product development.
BODITECH MED INC.
BODITECH MED INC. is a South Korean public company founded in 1998 with 541 employees in diagnostic device manufacturing.
Reasons to Buy this Report
- Market Entry Strategy : Comprehensive analysis of Mexico's specific market dynamics, regulatory environment, and competitive landscape enables informed market entry decisions and localized business strategy development.
- Growth Opportunity Identification : Detailed insights into Mexico's 7% CAGR trajectory and USD 29 million growth potential (2024-2029) help identify high-value segments and geographic regions for targeted investment and expansion.
- Rural Market Penetration : In-depth understanding of Mexico's rural healthcare accessibility initiatives and underserved region dynamics enables development of tailored solutions and distribution strategies for untapped market segments.
- Competitive Intelligence : Mexico-specific competitive analysis, market share data, and key player strategies provide actionable intelligence for positioning products and services effectively against local and international competitors.
- Regulatory & Reimbursement Insights : Detailed information on Mexico's healthcare regulations, reimbursement policies, and compliance requirements ensures successful product launches and sustainable market operations.
Frequently asked questions
What is the current size of Mexico's Point of Care Diagnostics Market?
Mexico's Point of Care Diagnostics Market is valued at USD 71.9 million in 2024.
What is the projected market size for Mexico by 2029?
Mexico's Point of Care Diagnostics Market is projected to reach USD 100.9 million by 2029.
What is the CAGR for Mexico's Point of Care Diagnostics Market?
Mexico's Point of Care Diagnostics Market is expected to grow at a compound annual growth rate (CAGR) of 7.0% from 2024 to 2029.
What are the primary drivers of growth in Mexico's Point of Care Diagnostics Market?
Mexico's market growth is driven by increasing healthcare accessibility in underserved regions, rising chronic disease prevalence, and growing adoption of rapid diagnostic technologies across clinical and non-clinical settings.
Where are Point of Care Diagnostics being adopted in Mexico?
In Mexico, POC testing devices are being increasingly adopted in hospitals, clinics, pharmacies, and home-care settings to improve diagnostic efficiency and patient outcomes.
RESEARCH METHODOLOGY
The study involved major activities to estimate the current market size of the Point of Care diagnostics market. Exhaustive secondary research was conducted to gather information on the market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain using primary research. Different approaches, such as top-down and bottom-up, were employed to estimate the total market size. After that, the market breakup and data triangulation procedures were used to estimate the market size of the segments and subsegments of the POC diagnostics market.
Secondary Research
This research study involved the extensive use of secondary sources, directories, databases such as Dun & Bradstreet, Bloomberg Businessweek, and Factiva, white papers, and Companies House documents. Secondary research was undertaken to identify and collect information for this extensive, technical, market-oriented, and commercial study of the POC diagnostics market. It was also used to obtain important information about the top players, market classification, and segmentation according to industry trends to the bottom-most level, geographic markets, and key developments related to the market. A database of the key industry leaders was also prepared using secondary research.
Primary Research
In the primary research process, various supply- and demand-side sources were interviewed to obtain qualitative and quantitative information for this report. Primary sources from the supply side included industry experts such as CEOs, VPs/Managing Directors, Marketing Heads/Directors, Sales Directors, Marketing/Sales Managers, Regional/Area Sales Managers, Export/Import Heads/Managers, and Other Market-Related Personnel from various companies and organizations operating in the POC diagnostics market. Primary sources from the demand side included Law Enforcement Agencies, Vice Presidents, C-level Executives, Department Heads, Enterprises, Individuals, Supply Management Teams of Hospitals, Clinic Personnel, and Laboratory Technicians.
Note 1: C-level primaries include CEOs, COOs, CTOs, and VPs.
Note 2: Other primary roles include sales, marketing, and product management.
Note 3: Companies are classified into tiers based on their total revenue. As of 2025: Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 = <USD 500 million.
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
Both top-down and bottom-up approaches were used to estimate and validate the total size of the POC diagnostics market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
Data Triangulation
The entire market was split into two segments when the market size was determined. Data triangulation and market breakdown were used as needed to complete the market engineering process and derive precise statistics for all segments.
Approach for deriving the market size and estimating market growth:
Using secondary data from paid and unpaid sources, the market rankings for the major players were determined through a thorough analysis of their POC diagnostic sales. Due to data restrictions, the revenue share in certain cases was determined after a thorough analysis of the product portfolio of big corporations and their individual sales performance. This information was verified at each stage by in-depth interviews with professionals in the field.
Market Definition
Point-of-care (POC) diagnostics refers to diagnostic testing performed at or near the patient's location, delivering rapid and accurate results to support immediate clinical decision-making. The market includes products such as blood glucose monitoring systems, infectious disease tests, cardiac biomarker assays, coagulation testing, blood gas and electrolyte analyzers, molecular diagnostics, pregnancy and fertility tests, urinalysis, and other rapid diagnostic solutions, serving hospitals, clinical laboratories, physician offices, ambulatory care facilities, retail clinics, pharmacies, and home healthcare settings.
Key Stakeholders
- Diagnostic device manufacturers
- Reagent and consumable suppliers
- Hospitals and clinical laboratories
- Physician offices and ambulatory care centers
- Pharmacies and home healthcare providers
- Medical device distributors
- Regulatory authorities
- Government and public health agencies
- Research organizations
- Healthcare IT providers
Report Objectives
- To describe, analyze, and forecast the POC diagnostics market, by product, sample, mode of purchase, technology, end user, and region
- To describe and forecast the POC diagnostics market for key regions, namely, North America, Europe, the Asia Pacific, Latin America and Middle East, and Africa
- To provide detailed information regarding drivers, restraints, opportunities, and challenges influencing the growth of the POC diagnostics market
- To strategically analyze the ecosystem, regulations, patenting trend, value chain, Porter’s five forces, and prices pertaining to the market under study
- To strategically analyze micromarkets1 with respect to individual growth trends, prospects, and contributions to the overall market
- To analyze market opportunities for stakeholders and provide details of the competitive landscape for market players
- To profile key players and comprehensively analyze their market shares and core competencies2 in the POC diagnostics market
- To analyze competitive developments such as collaborations, acquisitions, product launches, expansions, and R&D activities in the POC diagnostics market
Available customizations:
With the given market data, MarketsandMarkets offers customizations as per your company’s specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to 5)
Product Analysis
- Product matrix, which gives a detailed comparison of the product portfolios of each company
Geographic Analysis
- Further breakdown of the Rest of Asia Pacific POC diagnostics market into Vietnam, New Zealand, and other markets.
- Further breakdown of the Rest of Latin America POC diagnostics market into Colombia, Chile, Ecuador, and others.
- Further breakdown of the Rest of Europe POC diagnostics market into Belgium, Russia, the Netherlands, Switzerland, and others.
Get the Full Point of Care Diagnostics Market Report
Full forecast, segment splits, and company analysis for all Point of Care Diagnostics Market.
- Canada Point of Care Diagnostics Market
- US Point of Care Diagnostics Market
- Germany Point of Care Diagnostics Market
- France Point of Care Diagnostics Market
- UK Point of Care Diagnostics Market
- Italy Point of Care Diagnostics Market
- Spain Point of Care Diagnostics Market
- China Point of Care Diagnostics Market
- Japan Point of Care Diagnostics Market
- India Point of Care Diagnostics Market
- Australia Point of Care Diagnostics Market
- South Korea Point of Care Diagnostics Market
- Brazil Point of Care Diagnostics Market
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report